Intravascular lymphomatosis - An indolent or aggressive entity?

Vered Bogomolski-Yahalom, Izidore S. Lossos, Elimelech Okun, Yoav Sherman, Alexander Lossos, Aaron Polliack

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Intravascular lymphomatosis (IVL) is a rare malignancy characterized by neoplastic proliferation of lymphoid cells within the lumens of arteries, small veins and capillaries. We report four patients with IVL and review the recent world literature, relating to incidence, clinical features and possible therapy. In these cases diagnosis was established coincidentally in one patient after prostatectomy. This patient eventually had central nervous system involvement. In two other patients IVL was diagnosed from skin lesions. In the fourth case the diagnosis was established at post-mortem examination, where involvement of most organs was evident but particularly kidneys, myocardium, gastrointestinal tract and lymph nodes. Therapy was given to three patients, but the disease progressed in two and they both died with evidence of central nervous system involvement, while the third patient has had a good partial response to combination chemotherapy but has relapsed within two months of completing chemotherapy. As evident from our patients and the literature review IVL has a variable clinical course and currently, there appears to be no effective therapy for this rare disorder.

Original languageEnglish (US)
Pages (from-to)585-593
Number of pages9
JournalLeukemia and Lymphoma
Volume29
Issue number5-6
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Keywords

  • Intravascular lymphomatosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intravascular lymphomatosis - An indolent or aggressive entity?'. Together they form a unique fingerprint.

  • Cite this

    Bogomolski-Yahalom, V., Lossos, I. S., Okun, E., Sherman, Y., Lossos, A., & Polliack, A. (1998). Intravascular lymphomatosis - An indolent or aggressive entity? Leukemia and Lymphoma, 29(5-6), 585-593. https://doi.org/10.3109/10428199809050918